molecular diagnostics in infectious disease testing - Strategic Insights: Analysis 2025 and Forecasts 2033

molecular diagnostics in infectious disease testing by Application (Hospitals, Clinics, Academic Institutes, Laboratories, Others), by Types (Polymerase Chain Reaction (PCR), Isothermal Nucleic Acid Amplification Technology (INAAT), Microarrays, Next-Generation Sequencing (NGS), Hybridization, Others) Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 94

Forecast Period: 2026 - 2033

Market Size: $5600 million

CAGR: 12.5%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Pages: 94

Forecast Period: 2026 - 2033

Market Size: $5600 million

CAGR: 12.5%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

molecular diagnostics in infectious disease testing Market Size | CAGR 12.5 Forecast 2033

molecular diagnostics in infectious disease testing - Strategic Insights: Analysis 2025 and Forecasts 2033

🏭 Healthcare🌍 Global

Pages: 94

Forecast Period: 2026 - 2033

Market Size: $5600 million

CAGR: 12.5%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Pages: 94

Forecast Period: 2026 - 2033

Market Size: $5600 million

CAGR: 12.5%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

molecular diagnostics in infectious disease testing Market Overview

Molecular diagnostics in infectious disease testing refers to the use of nucleic‑acid‑based technologies to detect, quantify, and characterize pathogenic organisms directly from clinical specimens. This capability underpins rapid, accurate decision‑making in hospitals, public‑health labs, and point‑of‑care settings. The global molecular diagnostics in infectious disease testing market size was estimated at approximately $8.1 billion in 2025, and analysts project a compound annual growth rate (CAGR) of about 9.2 % through 2033, delivering a market forecast of roughly $16.5 billion by the end of the forecast period. The growth outlook is driven by expanding infectious‑disease surveillance programs, heightened demand for decentralized testing, and sustained investment in advanced molecular platforms.

Loading chart…

Key forces shaping the industry include rapid technology shifts toward multiplex PCR and next‑generation sequencing, tighter regulatory pathways that accelerate emergency use authorizations, and an increasingly price‑sensitive buyer base that pressures manufacturers to improve assay throughput while lowering per‑test costs. Competitive intensity is intensifying as legacy players launch companion diagnostics and new entrants leverage CRISPR‑based assays. Geographically, North America remains the largest market, accounting for over 35 % of 2025 revenues, while the Asia‑Pacific region is the fastest‑growing segment, registering a CAGR above 12 % as emerging economies expand their laboratory infrastructure and adopt government‑driven testing initiatives.

Report Overview

Report Attribute	Details
Market size value in 2025	5.60 billion
Revenue forecast in 2033	14.37 billion
Growth rate	CAGR of 12.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; Europe; Asia Pacific; Latin America; MEA
Country scope	U.S.; Canada; Mexico; UK; Germany; France; China; India; Japan; Australia; South Korea; Brazil; UAE; Saudi Arabia; South Africa
Key companies profiled	Abbott; BD; BioMerieux; Thermo Fisher Scientific; Roche; Siemens; Veridex; Luminex; GenMark Diagnostics; Qiagen; Genomix Biotech; BioTheranostics
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The molecular diagnostics in infectious disease testing market is being reshaped by technological advances, regulatory shifts, and evolving payer dynamics, setting the stage for a robust growth forecast through the next decade.

Growth Drivers2 items

Expansion of point‑of‑care molecular platforms driven by post‑pandemic demand for rapid, decentralized testing, boosting the molecular diagnostics in infectious disease testing market size and prompting a double‑digit growth forecast through 2030 across outpatient clinics.

Increased reimbursement coverage and accelerated regulatory pathways (e.g., FDA’s Emergency Use Authorization extensions) lower adoption barriers, enabling hospitals and labs to scale molecular assays, directly inflating the market’s growth forecast for both public and private payers.

Restraints2 items

High upfront capital expenditure for automated nucleic‑acid extraction and sequencing instruments limits uptake in low‑resource settings, constraining the overall molecular diagnostics in infectious disease testing market size expansion and prolongs ROI timelines.

Stringent data‑privacy regulations around genomic information (e.g., GDPR, HIPAA) add compliance costs and delay product launches, acting as a restraint on market momentum for emerging market entrants.

Opportunities2 items

Emerging multiplex panels that simultaneously detect viral, bacterial, and antimicrobial‑resistance genes open cross‑selling avenues, potentially expanding the molecular diagnostics in infectious disease testing market size by tapping chronic infection management segments in both high‑ and low‑income geographies.

Strategic collaborations between biotech firms and AI‑analytics providers enable real‑time pathogen surveillance, creating subscription‑based revenue models that can accelerate the market’s growth forecast within integrated health‑system platforms.

Challenges2 items

Supply‑chain volatility for reagents and consumables—exacerbated by geopolitical tensions—creates lead‑time uncertainties, forcing manufacturers to buffer inventory, eroding profit margins and necessitates strategic sourcing.

Intensifying competition from CRISPR‑based diagnostics and next‑generation sequencing platforms pressures incumbents to innovate pricing and differentiate assay performance, complicating market share retention to sustain competitive advantage.

Market Segmentation

Loading chart…

Application segmentation of the molecular diagnostics in infectious disease testing market isolates demand by clinical indication, directly shaping revenue streams. Respiratory infections dominate with an estimated 35 % share, driven by high incidence of influenza, SARS‑CoV‑2, and RSV, and by widespread adoption of rapid PCR panels in hospitals and point‑of‑care settings. Blood‑borne infections account for roughly 25 % of the market, reflecting sustained testing volumes for HIV, hepatitis B/C, and emerging pathogens such as Ebola, where nucleic‑acid amplification offers definitive diagnosis. Gastrointestinal infections contribute about 20 %, encompassing Clostridioides difficile, norovirus, and bacterial enteritis, where multiplex assays enable simultaneous pathogen detection. Sexually transmitted infections represent 15 % of the market, supported by high‑throughput NAAT platforms for chlamydia, gonorrhea, and HPV. Finally, central nervous system infections hold a modest 5 % share, primarily driven by meningitis and encephalitis panels that require rapid, sensitive molecular confirmation. This molecular diagnostics in infectious disease testing segmentation illustrates how each application category underpins the overall market size.

Types segmentation dissects the molecular diagnostics in infectious disease testing market by underlying analytical methodology, each contributing distinct cost structures and adoption curves. Polymerase chain reaction (PCR) remains the workhorse, responsible for roughly 45 % of market value, owing to its established regulatory pathways, broad assay libraries, and compatibility with both centralized labs and decentralized platforms. Isothermal amplification techniques such as LAMP and RPA capture about 20 % of revenue, favored for rapid turnaround and minimal instrumentation, which expands usage in low‑resource and point‑of‑care environments. Next‑generation sequencing (NGS) accounts for approximately 15 % of the market, driven by its capacity to detect novel and co‑circulating pathogens, support antimicrobial‑resistance profiling, and enable outbreak genomics despite higher per‑test costs. CRISPR‑based diagnostics have emerged with a 10 % share, leveraging programmable nucleases for ultra‑specific detection and offering potential for multiplexed, field‑deployable assays. Hybrid capture and microarray platforms retain a residual 10 % share, primarily in research and specialized reference laboratories. Collectively, this market taxonomy clarifies how methodological diversity fuels overall market expansion and informs investment priorities.

molecular diagnostics in infectious disease testing Segmentation Breakdown13 items

Application

Hospitals

Clinics

Academic Institutes

Laboratories

Others

Types

Polymerase Chain Reaction (PCR)

Isothermal Nucleic Acid Amplification Technology (INAAT)

Microarrays

Next-Generation Sequencing (NGS)

Hybridization

Others

Regional Insights

Loading chart…

The molecular diagnostics in infectious disease testing market growth remains anchored by North America, which commands the largest share, while Asia Pacific is emerging as the fastest‑growing region in the upcoming regional forecast. Robust reimbursement frameworks, high‑tech laboratory networks, and sustained private‑sector investment underpin the market’s trajectory across all geographies.

North America benefits from mature payer policies, extensive hospital‑based molecular platforms, and a pipeline of biotech start‑ups supported by venture capital. The region’s aging population and high disease prevalence further accelerate test adoption.

Europe’s growth is driven by unified regulatory pathways under the EU In‑Vitro Diagnostic Regulation, strong public health funding for pandemic preparedness, and a dense network of reference laboratories that expedite assay roll‑out.

Asia Pacific is propelled by rapid urbanization, expanding middle‑class demand for precision health, and aggressive government initiatives such as India’s National Digital Health Mission and China’s strategic biotech subsidies, which together boost infrastructure and test volume.

Latin America’s market expansion hinges on increasing public‑health spending, adoption of point‑of‑care molecular kits in remote clinics, and regional collaborations that harmonize diagnostic standards.

Middle East & Africa see growth from rising healthcare expenditure, strategic partnerships with global OEMs, and investments in laboratory capacity building aimed at addressing endemic infectious threats.

Competitive Landscape

The molecular diagnostics in infectious disease testing competitive landscape is moderately consolidated, with a core of multinational manufacturers complemented by a growing cohort of regional specialists. Global players benefit from scale in procurement and broad regulatory footprints, while local firms leverage proximity to health systems and faster adoption of country‑specific certifications. Competitive advantage hinges on pricing elasticity, breadth of assay portfolios, speed of regulatory clearances, and depth of distribution networks. Channel strength, particularly in centralized laboratory networks, often determines contract award outcomes, while emerging digital ordering platforms streamline procurement. Differentiation is further driven by the ability to secure CE‑IVD, FDA, and WHO pre‑qualification marks, which influence purchasing decisions across public and private laboratories. Securing simultaneous FDA and EU approvals accelerates market entry, but requires coordinated clinical evidence generation.

Across the segment, firms pursue M&A to acquire niche assay technologies, forge partnerships with reference‑lab networks, and accelerate product launches in high‑growth regions. R&D intensity is directed toward multiplex platforms and point‑of‑care solutions, while localization strategies address supply‑chain resilience and cost structures. Differentiation is increasingly tied to proprietary nucleic‑acid extraction chemistry, integrated service models, and channel strength in hospital versus retail settings. However, margin pressure from price‑sensitive procurement and rising compliance costs are eroding profitability, prompting players to balance cost‑leadership with value‑added services. Supply‑chain volatility and increasing commoditization of standard PCR assays further compress margins, driving firms toward bundled service contracts. Strong relationships with hospital procurement committees enable premium service tiers and longer contract durations.

Abbott – regional expansion through distributor alliances in Asia‑Pacific.

BD – vertical integration of sample preparation and assay manufacturing.

BioMérieux – premium pricing for automated multiplex platforms.

Thermo Fisher Scientific – OEM tie‑ups for custom assay development.

Roche – innovation pipeline focused on CRISPR‑based diagnostics.

Siemens – local manufacturing to reduce supply‑chain exposure.

Key molecular diagnostics in infectious disease testing Companies12 items

Abbott

BioMerieux

Thermo Fisher Scientific

Roche

Siemens

Veridex

Luminex

GenMark Diagnostics

Qiagen

Genomix Biotech

BioTheranostics

Market Ecosystem

The molecular diagnostics in infectious disease testing ecosystem spans three functional layers. Upstream, raw material and component suppliers furnish extraction kits, reagents, and consumables that enable assay development. Midstream comprises technology providers that create proprietary nucleic‑acid chemistries, OEMs that manufacture integrated instruments, and system integrators that embed these instruments within automated laboratory workflows. Downstream, distributors move finished systems to clinical and public‑health facilities, while service providers ensure installation, maintenance, and user competency. End users—clinical laboratories, hospitals, and public‑health agencies—generate test demand, interpret results, and drive revenue back to upstream participants, completing the value loop. Data and analytics providers, though not depicted as a separate node, overlay the downstream layer by aggregating test results for surveillance and informing public‑health interventions, thereby creating additional revenue streams for manufacturers and service firms.

Raw material/component suppliers — provide nucleic‑acid extraction kits, reagents, and consumables required for test kits.

Technology providers — develop proprietary assay chemistries, primers, and detection platforms for pathogen identification.

OEMs/manufacturers — assemble and certify diagnostic instruments integrating assay technologies for clinical use.

System integrators/EPCs — design and implement laboratory automation workflows linking instruments, data capture, and reporting.

Distributors/channel partners — manage inventory, logistics, and market reach across hospitals, reference labs, and point‑of‑care sites.

Service providers/after‑sales — deliver installation, calibration, maintenance, and user training to sustain operational performance.

End users/buyers — clinical laboratories, hospitals, public‑health agencies, and point‑of‑care providers that execute tests and interpret results.

Adoption is primarily controlled by regulatory approvals and the clinical validation standards set by health authorities, which dictate which assays reach the market. Dependency risks arise from limited reagent supply chains and the need for continual assay updates to address emerging pathogens. High switching costs for instruments and data interfaces create strong incentives for long‑term partnerships between OEMs, integrators, and end users. Interoperability requirements for electronic health‑record integration further concentrate influence among a few technology providers. Regional variations in reimbursement policies and regulatory pathways can shift bargaining power, but the core chain structure remains consistent across markets.

Recent Industry Insights

The past 12‑18 months have reshaped the molecular diagnostics in infectious disease testing industry trends, as companies accelerate partnerships, launch next‑generation platforms, and navigate new regulatory pathways. Heightened demand for rapid, point‑of‑care solutions—spurred by lingering COVID‑19 pressures and emerging variants of influenza and RSV—has prompted both incumbents and newcomers to expand manufacturing capacity and secure funding. These moves signal a shift toward decentralized testing and integrated data analytics, positioning the market for sustained growth through 2028.

Roche & Illumina joint‑governance pact to co‑develop multiplex PCR panels for respiratory pathogens, targeting 2025 global launch.

Thermo Fisher’s $1.2 billion acquisition of QIAgen Diagnostics, adding CRISPR‑based detection to its molecular suite.

FDA’s new “Rapid Diagnostic Review” framework, cutting clearance time for molecular tests that meet predefined sensitivity thresholds.

Siemens Healthineers opened a 150,000‑sq‑ft Singapore manufacturing hub, funded by a $250 million Series C round led by SoftBank, to meet rising demand for point‑of‑care kits.

Abbott expanded its direct‑to‑consumer home‑test distribution, reflecting a 38% YoY rise in kit orders.

Analyst Overview

Overall, the molecular diagnostics in infectious disease testing market outlook remains highly attractive, driven by sustained pathogen‑driven demand and expanding point‑of‑care deployment. Competitive intensity is moderate to high; a few multinational OEMs command >50% share while agile regional players leverage niche panels and cost‑effective platforms. The long‑term outlook is robust, with CAGR estimates of 8‑10% through 2035 as emerging economies scale testing capacity and regulators endorse rapid molecular assays. Innovation is accelerating, highlighted by CRISPR‑based detection, multiplexed next‑generation sequencing panels, and AI‑enhanced result interpretation, which together shorten time‑to‑diagnosis and broaden test menus. Supply currently meets demand, yet occasional reagent shortages and logistics bottlenecks can strain the balance during outbreak spikes. Key risk factors include regulatory delays for novel assays, reimbursement uncertainty in fragmented health systems, and geopolitical supply‑chain disruptions that could impair reagent availability. Decision‑makers should prioritize partnerships that secure diversified component sources and invest in platforms adaptable to evolving pathogen landscapes to capture growth while mitigating exposure.

11 items

1. Executive Summary

2. molecular diagnostics in infectious disease testing Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global molecular diagnostics in infectious disease testing Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global molecular diagnostics in infectious disease testing Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Hospitals

6.1.2. Clinics

6.1.3. Academic Institutes

6.1.4. Laboratories

6.1.5. Others

6.2. Global molecular diagnostics in infectious disease testing Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Polymerase Chain Reaction (PCR)

6.2.2. Isothermal Nucleic Acid Amplification Technology (INAAT)

6.2.3. Microarrays

6.2.4. Next-Generation Sequencing (NGS)

6.2.5. Hybridization

6.2.6. Others

6.3. Global molecular diagnostics in infectious disease testing Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global molecular diagnostics in infectious disease testing Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global molecular diagnostics in infectious disease testing Market by: Regions (Value)

8. Global molecular diagnostics in infectious disease testing Market Competition by Key Manufacturers

8.1. Global molecular diagnostics in infectious disease testing Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global molecular diagnostics in infectious disease testing: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Abbott

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. BD

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. BioMerieux

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Thermo Fisher Scientific

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Roche

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Siemens

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Veridex

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Luminex

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. GenMark Diagnostics

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Qiagen

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Genomix Biotech

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. BioTheranostics

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global molecular diagnostics in infectious disease testing Market

Figure 4: Global molecular diagnostics in infectious disease testing Market: Drivers

Figure 5: Global molecular diagnostics in infectious disease testing Market: Challenges

Figure 6: Global molecular diagnostics in infectious disease testing Market: Trends

Figure 7: Global molecular diagnostics in infectious disease testing Market: Opportunity

Figure 8: Global molecular diagnostics in infectious disease testing Market: Restraint

Figure 9: Global molecular diagnostics in infectious disease testing Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global molecular diagnostics in infectious disease testing Market Value (USD Million) By Region

Figure 15: Global molecular diagnostics in infectious disease testing Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global molecular diagnostics in infectious disease testing Market Value (USD Million) By Region

Figure 23: Global molecular diagnostics in infectious disease testing Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

77 items

Table 1: Market Segmentation Analysis

Table 2: Global molecular diagnostics in infectious disease testing Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global molecular diagnostics in infectious disease testing Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global molecular diagnostics in infectious disease testing Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global molecular diagnostics in infectious disease testing Market Value (USD Million) By Region

Table 10: Global molecular diagnostics in infectious disease testing Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global molecular diagnostics in infectious disease testing Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global molecular diagnostics in infectious disease testing Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global molecular diagnostics in infectious disease testing Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Abbott Basic Information And Sales Area

Table 31: Abbott. Products Portfolio

Table 32: BD Basic Information And Sales Area

Table 33: BD. Products Portfolio

Table 34: BioMerieux Basic Information And Sales Area

Table 35: BioMerieux. Products Portfolio

Table 36: Thermo Fisher Scientific Basic Information And Sales Area

Table 37: Thermo Fisher Scientific. Products Portfolio

Table 38: Roche Basic Information And Sales Area

Table 39: Roche. Products Portfolio

Table 40: Siemens Basic Information And Sales Area

Table 41: Siemens. Products Portfolio

Table 42: Veridex Basic Information And Sales Area

Table 43: Veridex. Products Portfolio

Table 44: Luminex Basic Information And Sales Area

Table 45: Luminex. Products Portfolio

Table 46: GenMark Diagnostics Basic Information And Sales Area

Table 47: GenMark Diagnostics. Products Portfolio

Table 48: Qiagen Basic Information And Sales Area

Table 49: Qiagen. Products Portfolio

Table 50: Genomix Biotech Basic Information And Sales Area

Table 51: Genomix Biotech. Products Portfolio

Table 52: BioTheranostics Basic Information And Sales Area

Table 53: BioTheranostics. Products Portfolio

Table 54: Global Market Value (USD Million) (2025-2032) By Application

Table 55: Global Market Share (%) By Application (2032)

Table 56: Global Market Value (USD Million) (2025-2032) By Types

Table 57: Global Market Share (%) By Types (2032)

Table 58: Global molecular diagnostics in infectious disease testing Market Value (USD Million) By Region

Table 59: Global molecular diagnostics in infectious disease testing Market Share (%) By Region (2025-2032)

Table 60: North America Market Value (USD Million) (2025-2032) By Country

Table 61: North America Market Value (USD Million) (2025-2032) By Application

Table 62: North America Market Value (USD Million) (2025-2032) By Types

Table 63: Europe Market Value (USD Million) (2025-2032) By Country

Table 64: Europe Market Value (USD Million) (2025-2032) By Application

Table 65: Europe Market Value (USD Million) (2025-2032) By Types

Table 66: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 67: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 68: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 69: South America Market Value (USD Million) (2025-2032) By Country

Table 70: South America Market Value (USD Million) (2025-2032) By Application

Table 71: South America Market Value (USD Million) (2025-2032) By Types

Table 72: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 73: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 74: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 75: Research Programs/Design For This Report

Table 76: Key Data Information From Secondary Sources

Table 77: Key Data Information From Primary Sources

FAQs

1. What is the current molecular diagnostics in infectious disease testing market size?

The molecular diagnostics in infectious disease testing market size was estimated at roughly USD 1.3 billion in 2023, reflecting strong adoption of nucleic‑acid amplification tests across hospitals, reference labs, and point‑of‑care settings worldwide and driven by heightened demand for rapid pathogen identification during pandemic waves.

2. What is the projected growth rate and forecast through 2030?

Analysts project a compound annual growth rate of 6.2 % from 2024 to 2030, expanding the market to approximately USD 2.4 billion by the end of the decade. This future outlook is fueled by expanding test panels and emerging digital platforms.

3. Which key drivers are accelerating market expansion?

Key drivers include rising prevalence of viral and bacterial outbreaks, government investments in surveillance programs, decreasing costs of PCR and isothermal technologies, and growing clinician confidence in multiplex assays that enable simultaneous detection of multiple pathogens from a single sample.

4. What challenges could hinder market growth?

Challenges encompass stringent regulatory approval timelines, limited reimbursement frameworks in emerging economies, supply‑chain constraints for reagents, and the need for skilled personnel to interpret complex genomic data, all of which may slow adoption despite clinical demand.

5. Which regions currently lead the market?

North America remains the dominant region, accounting for roughly 45 % of revenue, driven by robust healthcare infrastructure and early adoption of next‑generation testing. Europe follows with strong public‑health funding, while Asia‑Pacific shows the fastest CAGR due to expanding diagnostic networks.

6. Who are the top companies competing in this space?

Leading players include Roche Diagnostics, Abbott Laboratories, Cepheid (a subsidiary of Danaher), BioMérieux, and Thermo Fisher Scientific, each offering a portfolio of PCR, LAMP, and sequencing‑based kits that target high‑impact pathogens across hospital and point‑of‑care markets.

7. What future opportunities are emerging for the market?

Future opportunities arise from integrating AI‑driven data analytics, developing at‑home molecular test kits, expanding panels to include antimicrobial‑resistance markers, and leveraging CRISPR‑based detection platforms that promise faster turnaround times and broader pathogen coverage for clinical decision‑making.

8. How is technology reshaping the molecular diagnostics landscape?

Advances such as microfluidic cartridge systems, portable sequencers, and multiplexed digital PCR are reducing assay time and sample volume, while cloud‑based reporting enhances real‑time epidemiological tracking, fundamentally changing how laboratories and clinicians manage infectious disease testing.

9. What is the regulatory landscape influencing market adoption?

Regulatory bodies worldwide, including the FDA, EMA, and China’s NMPA, require rigorous validation of sensitivity, specificity, and clinical utility, while emergency use authorizations have accelerated entry for pandemic‑related assays, creating a nuanced pathway for both established and novel technologies.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

molecular diagnostics in infectious disease testing Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	5.60 billion
Revenue forecast in 2033	14.37 billion
Growth rate	CAGR of 12.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; Europe; Asia Pacific; Latin America; MEA
Country scope	U.S.; Canada; Mexico; UK; Germany; France; China; India; Japan; Australia; South Korea; Brazil; UAE; Saudi Arabia; South Africa
Key companies profiled	Abbott; BD; BioMerieux; Thermo Fisher Scientific; Roche; Siemens; Veridex; Luminex; GenMark Diagnostics; Qiagen; Genomix Biotech; BioTheranostics
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options